“Photo-Rimonabant”: Synthesis and Biological Evaluation of Novel Photoswitchable Molecules Derived from Rimonabant Lead to a Highly Selective and Nanomolar “Cis-On” CB1R Antagonist
[EN] 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES<br/>[FR] DERIVES AMIDES DE L'ACIDE CARBOXYLIQUE DE 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE 3 ET COMPOSES ASSOCIES EN TANT QU'ANTAGONISTES DE RECEPTEUR DE B1 DE LA BRADYKININE POUR LE TRAITEMENT DE MALADIES INFLAMMATOIRES
申请人:ELAN PHARM INC
公开号:WO2004098589A1
公开(公告)日:2004-11-18
Disclosed are compounds of formula I and II that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.
Compounds of formula (I) and their use as pharmaceutical.
化合物的分子式(I)及其作为药用的用途。
SUBSTITUTED BENZYLPYRAZOLES
申请人:Bayer Intellectual Property GmbH
公开号:US20140315934A1
公开(公告)日:2014-10-23
Compounds of formula (I) and their use as pharmaceutical.
化合物的分子式(I)及其作为药物的用途。
Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists
申请人:Tung S. Jay
公开号:US20050020659A1
公开(公告)日:2005-01-27
Disclosed are compounds that are bradykinin B
1
receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B
1
receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.
Selected substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists
申请人:Garofalo W. Albert
公开号:US20050032868A1
公开(公告)日:2005-02-10
Disclosed are compounds that are bradykinin B
1
receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B
1
receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.